BioSpace News Archive

-- New Three-Year Gene Therapy Data for Parkinson’s Disease Part of 30 Abstracts to be Presented at 2020 Psych Congress and the MDS Virtual Congress 2020 -- - INGREZZA® (valbenazine) Data Analyses from Long-Term Phase III Studies Demonstrate Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia - New Phase III Data Analyses of ONGENTYS® (opicapone) Support Treatment as Add-On Therapy to Levodopa/Carbidopa for Parkinson’s Patients with Motor F

CONMED Corporation announced that Curt R. Hartman, President, Chief Executive Officer and Chair of the Board, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference at 3:30 p.m. ET on Wednesday, September 16, 2020.

CooperCompanies (NYSE: COO) today announced financial results for its fiscal third quarter ended July 31, 2020. Revenue decreased 15% year-over-year to $578.2 million. CooperVision (CVI) revenue down 12% to $449.3 million, and CooperSurgical (CSI) revenue down 24% to $128.9 million. GAAP diluted earnings per share $1.12, down $1.28 or 53% from last year’s third quarter. Non-GAAP diluted earnings per share $2.28, down $0.95 or 30% fr

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect®·RNA (OR-100) collection device was included along with other devices in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to MiraDx Inc., a Los Angeles-based molecular genetics company. This is the fifth EUA

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 10:40 a.m. ET on Wednesday, September 9, 2020. To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upcoming virtual investor conferences. The details of the presentations are as follows: Wells Fargo 2020 Virtual Biotech Conference Fireside Chat:

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will participate in a fireside chat at the Citi 15 th Annual Biopharma Virtual Conference on Thursday, September 10, 2020 at 11:40 a.m. ET / 8:40 a.m. PT . Dan Faga, Executive Vice President and Chief Operating Officer, wil

Pieris today announced that members of the management team will participate in the following upcoming investor conferences

BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on September 1, 2020, the compensation committee of BridgeBio’s board of directors granted 10 new employees options to purchase an aggregate of 18,231 shares of the Company’s common stock with a per share exercise price of $27.62 and restricted stock units for an aggregate of 19,915 shares of the Company’s common stock.

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss